Skip to main content

Table 3 Study variables a

From: Efficacy and safety of a booster dose of influenza vaccination in solid organ transplant recipients, TRANSGRIPE 1-2: study protocol for a multicenter, randomized, controlled clinical trial

Category Variables
Demographic data Sex and age
Comorbidities COPD, diabetes, obesity, kidney failure, hepatic disease, AIDS, cancer, leukemia, connective tissue disease, cerebrovascular disease, other comorbidities
Previous vaccinations Influenza vaccination (seasons 2011–2012 and 2010–2011), influenza A H1N1 (2009) vaccination, pneumococcal conjugate vaccination, other immunizations
Solid organ Transplant Date, organ, immunosuppressive treatment, graft rejection history, use of monoclonal antibodies
Influenza infection records Confirmed influenza infection in previous season, confirmed influenza infection after study treatment, influenza severity, influenza treatment, influenza treatment outcome, date of recovery
Immune response Seroconversion and seroprotection rates (GMT, GMR), influenza virus–specific memory A- and B-cell responses, confirmed influenza infection during follow-up
Adverse events Dates, progress, intensity, expectability, causality, progress, toxicity degree
Concomitant treatments Indication, dose, frequency, administration route, start and end dates
  1. aCOPD, Chronic obstructive pulmonary disease; GMR, Geometric mean ratio; GMT, Geometric mean titers.